RxDoctor Payments Data

Karlene Bert

Nurse Practitioner · Modesto, CANPI 1053511378

Payments from drug & device makers

$1,495in general payments, 2019–2025

Across 52 payments — averaging $28.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$680
  • Mylan Specialty L.p.$390
  • Amgen$179
  • Viatris Specialty LLC$100
  • Amarin Pharma, Inc.$37
  • Biohaven Pharmaceuticals, Inc.$36
  • plus $74 from 3 others

What the payments were for

  • Food & beverage$1,495100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,495 in reported general payments places this provider in the 80th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$215,804
Medicare patients
182
Services billed
1,923

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TezspireTezepelumab-Ekko187$726,560
RinvoqUpadacitinib105$698,823
TrulicityDulaglutide95$96,438
LinzessLinaclotide130$78,803
VascepaIcosapent Ethyl219$76,748
Bydureon BciseExenatide Microspheres82$70,222
FarxigaDapagliflozin Propanediol79$48,055
OzempicSemaglutide46$46,365
MyrbetriqMirabegron93$44,312
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog123$41,727
Arnuity ElliptaFluticasone Furoate153$37,728
Breo ElliptaFluticasone/Vilanterol72$30,586
EliquisApixaban48$29,571
XareltoRivaroxaban47$27,657
Icosapent Ethyl107$23,708

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTezspire, Farxiga, Pulmicort Flexhaler$680$781,441291 claims
Novo NordiskOzempic$17$46,36546 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in Modesto

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →